Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. (FNCH) Revenue
Annual & quarterly revenue history · segment & region breakdown
FNCH · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsFinch Therapeutics Group, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | -$0.00B | -100.00% |
| 2023-12-31 | $0.00B | -$0.00B | -87.57% |
| 2022-12-31 | $0.00B | -$0.02B | -95.35% |
| 2021-12-31 | $0.02B | +$0.01B | +140.08% |
| 2020-12-31 | $0.01B | -$0.00B | -23.98% |
| 2019-12-31 | $0.01B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Finch Therapeutics Group, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Finch Therapeutics Group, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Finch Therapeutics Group, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FNCH revenue · 4 questionsFNCH's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · Finch Therapeutics Group, Inc. SEC filings · GAAP · Finch Therapeutics Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026